Abstract Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing antivector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes. This chapter describes the features of four viral vector systems based on poxviruses, adenoviruses, alphaviruses and lentiviruses and recent results following their use with a particular emphasis on clinical research, highlighting the challenges and successes.

Keywords Genetic vaccines • Viral-vectored vaccines • Adenovirus • Poxvirus • Alphavirus • Lentivirus • Heterologous prime-boost

4.1 Genetic Vaccines: The New Frontier

Vaccines have been undeniably successful at inducing immune responses, most notably neutralizing antibodies that prevent viral or bacterial infections. However, to protect against more complex pathogens such as Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), Plasmodium falciparum, Mycobacterium tuberculosis (TB) or cancers it will be necessary to engage the other arm of the adaptive immune system: T lymphocytes. Pre-clinical and clinical evidence supports the role of T cell
immunity and in particular CD8+ T cells in the control and/or clearance of these diseases (Kim and Ahmed 2010). Therefore, a rapidly expanding field in vaccinology is the development of so-called genetic vaccines. These are designed to induce antigen-specific CD4+ and CD8+ T cells of sufficient magnitude and necessary phenotype or effector function that directly contribute to pathogen clearance, rather than only CD4+ T cell help for B cells leading to protective antibody responses. One way to induce a T cell response against a given antigen is to express that antigen intracellularly, along with suitable pathogen-derived innate activators, through gene delivery; genetic or gene-based vaccines attempt to use physiological antigen processing and Major Histocompatibility Complex (MHC) class I presentation to activate a CD8+ T cell response. Genetic vaccines as being capable of stimulating both antibodies and CD8+ T cells hold real promise for achieving efficacy. Table 4.1 lists pros and cons of genetic vaccines.

DNA vaccines were initially thought to be the ideal way to induce T cell responses (Liu 2010; Reyes-Sandoval and Ertl 2001). After intramuscular or intradermal injection they express the encoded antigen inside the host cells resulting in both cellular and humoral immunity. These vaccines are simple to produce and can be manipulated to co-express cytokines or other molecules intended to enhance the immune response, and are simple to produce. Unfortunately, the early successes in pre-clinical studies did not translate into clinical trials, and whereas DNA vaccines are safe to use and do induce T cell responses in humans, these are of a very low magnitude. Efforts to increase immunogenicity by use of new devices such as the ‘gene-gun’ resulted in more efficient delivery such that the dose could be considerably reduced, but the response was not increased. Despite several efforts to find an adjuvant to increase the immunogenicity of DNA vaccines in humans, success has so far been modest (Baden et al. 2011). The same holds true for peptide-based vaccines.

### Table 4.1 Advantages and disadvantages of genetic vaccines

| Advantages | Disadvantages |
|------------|---------------|
| Subunit vaccination, no risk for infection | Limited to protein immunogens (not useful for non-protein based antigens such as bacterial polysaccharides) |
| MHC class I and II presentation | Risk of affecting genes controlling cell growth |
| Ease of development and production | Lower antibody response as compared to protein and live-attenuated vaccines |
| Stability of vaccine for storage and shipping | |
| Cost-effectiveness | |
| Obviates need for peptide synthesis, expression and purification of recombinant proteins and the use of adjuvants | |
| Long term persistence of immunogen | |
| Correct folding and post-translational modifications of the antigens, due to in vivo expression | |

*MHC* Major Histocompatibility Complex
Engineered Viruses as Vaccine Platforms (Nardin 2010; Perez et al. 2010). Other research has concentrated on developing adjuvants to increase the T cell immunogenicity of protein vaccines, (Foged et al. 2011), but again although responses can be induced in preclinical studies, they are not of high magnitude and in many cases have not yet been tested in clinical studies.

Numerous viral vectors are being studied for use in gene-based vaccine strategies. Virus-derived vectors offer several advantages over traditional vaccine technologies, the first being a very efficient delivery of the exogenous gene into target cells. Other advantages include high level production of protein antigens within cells of the immunized host, potential adjuvant effects of the viral vector system itself and the possibility of efficient delivery of antigen directly to components of the immune system.

The most commonly used vectors are derived from adenoviruses, poxviruses, alphaviruses and lentiviruses. There is a wide consensus that the ideal vector for the development of genetic vaccines must be endowed with many properties, e.g. the quality and the quantity of the immunological response induced against the encoded antigens, its safety and its “productivity” in conditions compatible with the industrial scale. A comparative assessment of strengths and weaknesses of various genetic vectors is reported in Table 4.2.

Features of the four viral vector systems mentioned above and recent results following their use will be reviewed with a particular emphasis on clinical research, highlighting the challenges and successes, and looking towards their future deployment.

4.2 Viral Vector Platforms

4.2.1 Adenovirus Vectors

Among the viral vectors investigated for vaccine purposes, adenovirus (Ad) vectors have received considerable attention and today they stand among the most potent tools available for induction of antibody and CD8+ T cell responses in mice, primates and humans (Barefoot et al. 2008; Barouch 2010; Bett et al. 2010; Harro et al. 2009; Ledgerwood et al. 2010; Liu et al. 2009; Tatsis and Ertl 2004). Human adenoviruses are attractive viral vectors for a number of reasons. They possess a stable virion so that inserts of foreign genes are not deleted. Also adenoviruses have wide cell tropism and the transferred information remains epichromosomal, thus avoiding the risk of insertional mutagenesis. Replication-defective adenoviruses can be engineered by deletion of genes from the E1 locus, which is required for viral replication, and these viruses can be propagated easily with good yields in complementing cell lines expressing E1 from adenovirus serotype 5 (Ad5), such as HEK293 and PER.C6 (Tatsis et al. 2006).

Preclinical and clinical results showed superiority of adenovirus-vectored vaccines based on the most common human Ad5 for the induction of T cell responses in
| Vector                        | Insert size | Immune response | Advantages                                                                 | Disadvantages                     | Clinical phase |
|------------------------------|-------------|-----------------|-----------------------------------------------------------------------------|-----------------------------------|----------------|
| Adenovirus                   | 8–9 kb      | Ab, CD8⁺, CD4⁺  | Wide tropism,                                                               | Prior immunity                    | II             |
| Ad5                          |             |                 | Infects dividing and non-dividing cells                                     |                                   |                |
|                              |             |                 | No integration                                                              |                                   |                |
|                              |             |                 | Physically and genetically stable                                           |                                   |                |
|                              |             |                 | Produced to high viral titres                                              |                                   |                |
|                              |             |                 | Intrinsic adjuvant activity in addition to above: Many strains available     |                                   |                |
| Rare hAd serotypes           |             |                 | No/low prior immunity                                                       | Poorly immunogenic                 | I              |
| Chimpanzee derived Ad        |             |                 | Some highly immunogenic strains                                             |                                   | II             |
| Poxviruses                   | >10 kb      | CD4⁺            | Room for very large inserts                                                | Prior immunity in smallpox vaccinees | II             |
| MVA, NYVAC                   |             |                 | Broad cell tropism                                                          |                                   |                |
|                              |             |                 | Intrinsic adjuvant activity                                                  |                                   |                |
|                              |             |                 | Safe                                                                        | Not good as primer                |                |
|                              |             |                 | Excellent booster                                                           |                                   |                |
| ALVAC, FPV                   |             |                 | No prior immunity                                                           | Weaker immunogens than mammalian Pox | III            |
| Alphaviruses                 | 8 kb        | Ab, CD8⁺        | High transgene expression                                                   | Limited insert capacity            | I              |
|                              |             |                 | No integration                                                              |                                   |                |
|                              |             |                 | No prior immunity                                                           | Kills transfected cells            |                |
|                              |             |                 | Targets DCs                                                                 | No packaging cell line            |                |
|                              |             |                 | Safe in animals                                                             |                                   |                |
| Lentiviruses                 | 7 kb        | Ab, CD4⁺, CD8⁺  | Infects dividing and non-dividing cells                                     | Safety concerns due to integration | Preclinical    |
| Integrating                  |             |                 | Prolonged transgene expression                                              |                                   |                |
| Integration defective        |             |                 | Low anti-vector immunity                                                    |                                   |                |
|                              |             |                 | Improved safety                                                             | Low transgene expression, requires high dosage |                |

Ab antibody, Ad adenovirus, ALVAC canarypox vectors, DC dendritic cell, FPV fowlpox vectors, MVA modified vaccinia Ankara, NYVAC attenuated vaccinia virus strain.
animal models and in Phase I studies in humans (Casimiro et al. 2003, 2004; Duerr et al. 2006). Preclinical studies of Ad5 vectors include vaccines against Ebola, Severe Acute Respiratory Syndrome (SARS), HIV and Anthrax (Bangari and Mittal 2006; Barouch 2010; Shiver et al. 2002; Sullivan et al. 2006) and clinical studies of Ad5 vectors encoding HIV, TB and Ebola antigens have been completed or are in progress (Catanzaro et al. 2006; Ledgerwood et al. 2010; McElrath et al. 2008; Priddy et al. 2008).

However, adenovirus is highly immunogenic per se and Ad vector-specific immune responses can result in a lack of prolonged expression of newly delivered genes upon re-administration of the same vector (Lasaro and Ertl 2009). More importantly, a major problem is that most humans have high titres of neutralizing antibodies against several adenovirus serotypes including Ad5 owing to exposure since childhood, negatively affecting their performance as vectors (Lasaro and Ertl 2009). Recent studies have shown that pre-existing immunity to Ad5 is capable of significantly blunting the immunological response induced by Ad5 vectored vaccines in rodents, in non-human primates and in Phase I clinical trials in humans (Casimiro et al. 2003; Catanzaro et al. 2006; McElrath et al. 2008; Priddy et al. 2008).

Various attempts have been made to overcome the problem of pre-existing immunity to Ad5, and thus exploit the full potential of the adenovirus vectors for the development of vaccines. One strategy is the identification and development of rare human serotypes such as Ad11, Ad24, Ad26, Ad35 and Ad28 (Geisbert et al. 2011; Kahl et al. 2010; Lemckert et al. 2005; Radosevic et al. 2010; Soloff et al. 2009). Adaptation of these alternative serotypes requires a methodical process of research and development, and safety testing. Furthermore, data suggests that these rare serotypes may be less immunogenic than Ad5 (Colloca et al. 2012).

Another strategy is the modification of the Ad5 capsid, a protein shell that contains hexon and penton subunits. Because host antibodies that neutralize Ad5 are directed against the hypervariable regions (HVRs) of the hexon subunit, Roberts and colleagues (Roberts et al. 2006) exchanged HVRs of Ad5 with those of the rare adenovirus serotype 48 (Ad48) generating a chimaeric adenovirus that could potentially evade the neutralizing antibody response against Ad5. The resulting virus retained its ability to grow in culture and, importantly the immunogenicity of the chimaera was comparable to that of Ad5. When the chimaera was administered to mice or monkeys that had antibody immunity to Ad5, there was no decrease in the immunogenicity of the vector. These data provide a proof-of-concept that viral vaccine vectors can be engineered to evade pre-existing immunity but vaccine developers will have to show that these HVR-chimaeric Ad5 viruses can be manufactured, that they have stable gene inserts, can pass regulatory review and, finally are immunogenic in humans with pre-existing immunity.

Adenoviruses isolated from chimpanzees (ChAd) have also been well characterized and developed as vectors (Farina et al. 2001; Roy et al. 2011; Tatsis et al. 2006). Simian adenoviruses are not known to cause pathological illness in humans and have low/no seroprevalence (0–18%) in the human population (Colloca et al. 2012; Lasaro and Ertl 2009). In Equatorial Africa, the natural habitat for chimpanzees, seroprevalence is higher, but still significantly below that of Ad5. The first report on the use
of ChAd vectors involved AdC68 expressing rabies virus glycoprotein and showed induction of high level of protective antibodies in mice (Xiang et al. 2002). Simian adenovectors were then utilized as T cell vaccines for HIV, inducing virus-specific CD4+ and CD8+ T cell responses in mice and macaques (Fitzgerald et al. 2003; Reyes-Sandoval et al. 2004) and for pre-erythrocytic malaria vaccines (Capone et al. 2010; Reyes-Sandoval et al. 2008). Very recently Colloca and colleagues reported a large screening of several adenoviruses isolated from chimpanzees and identified several adenoviruses that meet the necessary requirements for vaccine development (Colloca et al. 2012). In chimpanzee adenoviruses the E1 locus can be deleted to render virus replication deficient and to allow trans-complementation in Ad5 E1 complementing cell line. Chimpanzee derived adenoviruses exhibit high sequence similarity and same genomic organization to human adenoviruses and can be classified in subgroups based on sequence homology of the hexon protein. Phylogenetic analysis of the hexons of simian and human adenoviruses shows substantial overlap indicating that there is no clear sequence feature that distinguished a simian from a human adenovirus. Indeed, these sequences suggest one large family of higher primate adenoviruses. The potency of chimpanzee derived Ad vectors were assessed in mice, macaques and, recently, in humans (Barnes et al. 2012; Colloca et al. 2012; O’Hara et al. 2012; Sheehy et al. 2011). The T cell immunogenicity of some of these vectors matched or even exceeded the immunogenicity of the standard Ad5 vector used as a comparator. The safety of these vectors has been similar to that of human adenovirus vectors suggesting that they might be suitable for widespread use.

4.2.2 Poxvirus Vectors

In addition to adenovirus vectors, poxviruses are among the most heavily exploited for vaccine development. This is largely attributable to the extensive and successful use of the smallpox vaccine (and the related modified vaccinia Ankara, MVA) which provided knowledge of human safety together with a series of properties including: the large gene capacity for the insertion of a foreign gene; the broad tropism of the virus for mammalian cells; the production of antigen for a short period of time and the localization of the virus in the cytoplasm thus avoiding integration risk that might occur with a retroviral vector. Vaccines based on poxviruses are derived from vaccinia virus or members of the Avipox genus. Vaccinia-HIV recombinants have been evaluated in clinical trials, however largely due to concerns over use of replicating vectors, safer non-replicating poxvirus vectors have been the focus of extensive development. These attenuated derivatives of vaccinia virus used as vaccine platforms include: NYVAC, derived from the Copenhagen strain of vaccinia and rendered replication incompetent by 18 specific engineered deletions (Parrino and Graham 2006); the avipox vectors canarypox (ALVAC) and fowlpox (FPV) restricted to growth in avian cells, can infect mammalian cells but do not replicate (Franchini et al. 2004) and MVA. The latter, originally developed as a smallpox vaccine, was obtained following extensive serial passage on primary chicken embryo fibroblasts.
During this process of attenuation, MVA underwent deletion of 31 kb (~15%) of its genome, as compared to its parental strain, including a number of genes that contribute to viral evasion from host immune responses and that determine virus host range (Antoine et al. 1998; Meyer et al. 1991). As a result, MVA is unable to replicate productively in most mammalian cell types, including primary human cells. The resultant inability of MVA to undergo more than one infection cycle in a human host has imbued this virus with inherent safety that was demonstrated historically through the immunization of ~120,000 individuals during the smallpox eradication campaign. More recently, the safety of MVA has been demonstrated in pre-clinical studies of immune-deficient mice and immune-suppressed macaques (Stittelaar et al. 2001; Wyatt et al. 2004) and in Phase I clinical trial evaluations of MVA as a next-generation smallpox vaccine (Parrino et al. 2007). The desirable safety profile exhibited by MVA, in concert with its ability to express high levels (and large numbers) of foreign genes, has rendered MVA a leading candidate for evaluation as a vaccine vector against an array of infectious diseases and human cancers.

### 4.2.3 Alphavirus Vectors

Alphaviruses that are being developed as vaccine vectors include *Venezuelan equine encephalitis virus* (VEE), *Sindbis virus* (SIN), *Semliki forest virus* (SFV), and VEE-SIN chimaeras (Greer et al. 2007; Thornburg et al. 2007). Alphaviruses are single-stranded positive-sense RNA viruses that replicate in the cytoplasm of infected cells, and therefore have no potential for integrating into the host genome. Originally, to circumvent safety concerns, alphavirus vectors have been engineered as non-replicating replicon particles in which genes encoding structural products are deleted to accommodate a foreign gene of up to 5 kb, while structural proteins are provided *in trans* from two helper transcripts that lack a packaging signal. Importantly, the vector is naturally targeted to dendritic cells (DCs) in draining lymph nodes, where the transgene is expressed at high levels, leading to good immune responses (Davis et al. 2002). Immunogenicity is further enhanced as the self-amplification of the vector RNA occurs through double-stranded RNA intermediates which stimulate activation of the interferon cascade and multiple innate signaling pathways (Naslund et al. 2011). The vector also induces apoptosis in some cells types and the release of apoptotic bodies that are efficiently taken up by antigen presenting cells (APCs) can result in enhanced immune cross-priming (Perri et al. 2003). These features and the overall lack of pre-existing immunity against alphaviruses in the human population underscore their potential as vaccine vehicles.

Three types of vector have been developed: virus-like particles (VLPs), layered DNA-RNA vectors and replication-competent vectors. VLPs contain replicon RNA that is defective since it contains a cloned gene in place of the structural protein genes, and thus are able to undergo only one cycle of expression. They are produced by transfection of vector RNA, and helper RNAs encoding the structural proteins. Layered DNA-RNA vectors express the SFV replicon from a cDNA copy via a
cytomegalovirus promoter. Replication-competent vectors contain a transgene in addition to the structural protein genes. VEE-based propagation-defective virus-like replicon particles (VRP) have been shown to induce high titers of antibodies and robust antigen-specific T cell responses against encoded antigens in mice (Bernstein et al. 2009; Davis et al. 2002; Durso et al. 2007; Greer et al. 2007; Naslund et al. 2011; Perri et al. 2003) and more recently in healthy human subjects (Bernstein et al. 2009). At the same time, neutralizing anti-vector immunity does not appear to preclude benefit from repetitive booster vaccinations in mice (Gupta et al. 2006) as opposed to other viral vectors.

VEE/SIN chimaeras have been developed because of safety concerns. VEE is pathogenic in humans, in contrast to SIN which is non-pathogenic. In mice, chimeric vectors in which VEE contributes the replicon component and SIN the envelope glycoprotein packaging components have been shown to elicit potent immune responses as VEE itself, with both being superior to SIN or a SIN-VEE chimera (containing the SIN replicon component and VEE packaging components) (Perri et al. 2003). The greater responses induced by VEE may relate to greater levels of in vivo replication or the resistance of VEE to α and β interferons. Subsequent studies in macaques demonstrated that the chimeric VEE/SIN vectors elicited more potent systemic and mucosal immune responses to an inserted HIV envelope gene product compared to the SIN vector (Gupta et al. 2006). A combination approach involving priming with VEE/SIN replicons encoding HIV and Simian immunodeficiency virus (SIV) genes followed by boosting with HIV envelope protein elicited both cellular immunity and neutralizing antibodies and resulted in significantly lower acute viremia following exposure to Simian/Human immunodeficiency virus (SHIV) SF162P4 (Xu et al. 2006).

### 4.2.4 Lentivirus Vectors

Recently, recombinant lentiviral vectors (LVs) have gained substantial interest as an alternative method for eliciting antigen specific T-cell immunity (Collins and Cerundolo 2004; Collins and Esslinger et al. 2003; He et al. 2005; Hu et al. 2011). Immunization with LVs has been observed to induce potent and durable T cell responses in preclinical models. This is likely related to their capacity to transduce non-dividing cells, including DCs in the target tissues, and to enable persistent antigen presentation through high level expression of transgenes and low interfering anti-vector immune responses. It has been shown that LVs encoding HIV-1 polyepitopes induce broad CD8⁺ responses in mice (Iglesias et al. 2007), and that a single intramuscular administration of HIV-based LVs expressing viral antigens elicits strong cell-mediated immune responses (Buffa et al. 2006). Importantly, Beignon and colleagues recently provided the first evidence that an LV expressing SIV Gag protein was able to induce control of viral replication in monkeys challenged with high dose of SIV (Beignon et al. 2009). To fully harness the great potential of DCs as the “gatekeeper” for initiating and maintaining immunity, Yang and colleagues (Yang et al. 2008) reported the generation of a LV system
bearing a mutated glycoprotein derived from the SIN capable of targeting DCs through binding to the specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN).

Despite the desirable advantage of LVs to effectively deliver transgenes into DCs, vector integration in the host cell genome has provoked safety concerns over the consequences of insertional mutagenesis (Bokhoven et al. 2009; Montini et al. 2006). In order to improve the safety profile of LVs, considerable efforts have been made to generate integration-deficient LVs (IDLVs) by interrupting the function of integrase or its attachment sites in the vector backbone (Wanisch and Yanez-Munoz 2009). Although the integration is specifically inhibited, the resulting IDLVs can accomplish transient gene transfer to dividing cells and maintain durable transgene expression in non-dividing cells (Philippe et al. 2006). Initial experiments involving a single dose injection of IDLV encoding the envelope protein of either HIV-1 (Negri et al. 2007) or West Nile virus (Coutant et al. 2008) resulted in significant and prolonged immune responses against the delivered antigen.

Based on recent reports showing the potential of IDLVs for inducing antigen-specific immune responses upon in vivo immunization against viral or tumor antigens (Hu et al. 2009, 2010; Karwacz et al. 2009; Negri et al. 2011) in mouse models, further development in terms of bulk production (Lopes et al. 2011) and validation of IDLVs, including comparison with other vaccine protocols and use in non-human primate models, are warranted.

### 4.3 Enhancing Immunogenicity

#### 4.3.1 Heterologous Prime-Boost Regimens

The main limitation of vaccination approaches based on viral vectors is linked to the induction of anti-vector immunity after the first immunization. In fact, repeated administration of both recombinant adenoviruses and MVA vaccine vectors typically results in an increasingly diminished efficacy of such booster immunizations due to the elicitation of vector-specific neutralizing antibody responses (Casimiro et al. 2004; Hirsch et al. 1996). Several studies have shown that priming/boosting with different vaccine vectors elicits higher immune response to the transgene-encoded antigen than repeated vaccination with an individual vector. Thus the combined use of these vectors, generally defined heterologous prime-boost regimen, is the best way to overcome the antiviral immunity induced by the first vaccination while maximizing the host response to the vaccine insert.

Initially, heterologous prime-boost protocols with common vaccine inserts often used a DNA plasmid to prime the immune system; however, more recently interest has grown in the combined use of different viral vectors and in how their sequence of administration can influence the magnitude and nature of the induced immune response. Multiple approaches have now been tested in both animal models and humans, including DNA-MVA, DNA-NYVAC, FPV-MVA, Ad-MVA, heterologous
Ad-Ad, and DNA-Sendai virus, targeting a wide range of diseases from malaria, HIV-1, TB and HCV to cancers (Table 4.3). A consistent observation throughout all of these studies is the differential ability of certain vectors to prime or boost responses. DNA vaccines and FPV are good priming vectors, whereas poxviruses (MVA and NYVAC) are consistently able to boost T cell responses that are primed by other means. The utility of MVA-based vaccines to prime immune responses against foreign antigens appears to be limited due to unfavorable competition for immunodominance between the relatively large number of vector-specific gene products (Antoine et al. 1998) and the much smaller number of intended vaccine antigens (Smith et al. 2005b). A large body of data now indicates that, in general, recombinant Ad can prime T cell and B cell responses remarkably well. Therefore, an optimal regimen would use adenovirus first to prime and MVA later to boost the previously vaccine induced immune response. An immunization protocol based on adenovirus as prime followed by MVA has demonstrated to be a powerful strategy to induce potent and durable T cell responses. This strategy enabled induction of protective immune response against mouse malaria (Reyes-Sandoval et al. 2010) and SIV challenge in rhesus monkeys (Wang et al. 2010).

Recent work has established the use of prime-boost immunization regimens to induce B cell as well as T cell responses, in particular Ad-MVA (Draper et al. 2008), heterologous Ad-Ad (Liu et al. 2009) or viral vector prime followed by a protein boost (Draper et al. 2010; Durso et al. 2007) harnessing the ability of the viral vector to induce potent CD8+ T cell response and of the protein to induce high antibody titers and CD4+ T cells. The induction of both arms of the adaptive immune response is likely to be beneficial for protection against pathogen such as malaria parasites, and many viruses. A better understanding of how different viral vectors can affect the induction of B cell responses is essential to improve the rational design of vaccines and prime-boost strategies tailored to induce optimal antibody response.

4.3.2 Fusion Strategies Which Enhance T Cell Responses

Even though viral vector vaccines stand among the most potent platforms for induction of T cell responses, it is apparent that better vaccines are still needed to improve on magnitude, breadth or quality of the induced T cell response. Experimentally, immunogenicity may be improved by co-administration of cytokines and/or pathogen associated molecular patterns, and by fusion of antigen into molecular domains that enhances antigen presentation. For a substantial amount of time, the use of cis acting sequences for enhancing the efficacy of vaccination was DNA vaccine territory and there are not many strategies to increase the response to adenovirus vaccine vectors that have been published so far (Holst et al. 2010). It is tempting to speculate that viral vectored vaccines contain sufficient pathogen-associated molecular patterns to substitute for many cytokines co-administered with the vaccine. Compared to DNA vaccines, viral vectors more efficiently enters and transduce cells, including professional antigen presenting cells, generally induce very high levels of protein
| Vectors and regime | Pathogen/disease | Antigen | Developer | Clinical phase |
|--------------------|------------------|---------|-----------|----------------|
| Ad5                | *Plasmodium falciparum* | CSP and AMA1 | NMRC and GenVec | I/IIa          |
| ChAd63/MVA         | *P. falciparum* | ME-TRAP, MSP1, AMA1 | University of Oxford and Okairos | IIa |
| Ad35               | *P. falciparum* | CSP | Crucell | I              |
| BCG/MVA            | *Mycobacterium tuberculosis* | 85A | University of Oxford and Emergent BioSolutions | IIb |
| BCG/Ad35           | *M. tuberculosis* | 85A, 85B and 10.4 | AERAS and Crucell | I |
| ChAd3 and Ad6      | HCV | NS3, NS4 and NS5 | Okairos and University of Oxford | I |
| DNA/NYVAC          | HIV-1 | Gag-Pol-Nef and Env | EuroVacc | I |
| DNA/MVA            | HIV-1 | Gag-Pol and Env | GeoVax | IIa |
| DNA/Ad5            | HIV-1 | Gag-Pol-Nef and Env | VRC, NIAID (NIH) and GenVec | II |
| ALVAC/AIDSVAX gp120| HIV-1 | gp160 and gp120 | Sanofi Pasteur and Global Solutions for Infectious diseases | III |
| Ad5 and Ad6        | HIV-1 | Gag-Pol-Nef | Merck | II |
| Ad5                | Cancer | CEA | Etubics | I |
| Alphavirus replicon| CMV | gB and pp65/IE1 | AlphaVax/Novartis | I |
| VACV and ALVAC or FPV | Cancer | CEA | NIH | I/II |
| MVA                | Colorectal, renal and prostate cancer | 5T4 | Oxford Biomedica | I-III |
| MVA                | Lung cancer | MUC1 | Transgene SA | IIb |
| Lentivirus          | Melanoma | MART1 | Caltech and UCLA | I |
expression in the transduced cells, and induce substantial innate immune activation. In this regard, they are close to a natural infection or vaccination with live attenuated vaccines, but with an improved safety profile. A down-side is that vector antigens compete with the encoded vaccine antigen and focuses the response on immunodominant epitopes (Schirmbeck et al. 2008). In a search for adenovirus vaccine modifications which might lead to broader T cell responses, Holst and coworkers decided to improve MHC class II antigen presentation by covalently linking the encoded antigen to the MHC class II associated invariant chain (Holst et al. 2008). Surprisingly, this strategy improved not only CD4+ T cell responses, but also the kinetics, breadth, magnitude and durability of the CD8+ T cell response via increased MHC class I presentation (Holst et al. 2011).

A different strategy to generate more potent T cell responses using adenovirus vector, has been recently described (Appledorn et al. 2010). This strategy uses an Ad5 vector expressing a potent toll-like receptor (TLR) agonist derived from Eimeria tenella (EA) as an adjuvant to improve immune responses from an Ad5-based HIV Gag vaccine. Expression of rEA elicited significantly increased TLR mediated innate immune responses as measured by the influx of plasma cytokines and chemokines, and activation of innate immune responding cells in mice. Therefore, simultaneous expression of rEA, or potentially other similar TLR ligands from an Ad vector, can serve to enhance cell mediated immunity responses to pathogen derived antigens expressed from the same vectors. Other approaches to improve on viral vector-induced immunity were based on antigen linked to the herpes virus VP22 protein and calreticulin which have been tested in SIN replicon particles (Cheng et al. 2002) and vaccinia vectors (Hsieh et al. 2004), respectively, and the Herpes viral glycoprotein D, which has been tested using Ad vector (Lasaro et al. 2008).

If highly active cis acting agents can be identified for viral vectors there is a theoretical possibility of boosting antigen specific immune responses while inducing negligible vector immunity. Future studies are needed to determine if this theoretical opportunity can be exploited to allow efficient and repeated administration of virus vectored vaccines.

4.4 Viral-Vectored Vaccines in Clinical Trials

There are no vaccines based on viral vectors or vaccines that act directly by T cell mediated immunity currently on the market for use in humans. However, a vaccine for Japanese encephalitis virus (JEV) using an attenuated Jelllow fever virus (YFV-17D) encoding the JEV preM-Env protein, developed by Sanofi Pasteur, has completed Phase III trials and marketing authorization applications in endemic areas has been filed (Appaiaghari et al. 2010). The JEV vaccine known as IMOJEV® is therefore poised to be the first human viral vectored vaccine on the market. There are also 12 viral vector vaccines currently in use for veterinary diseases. The approved vaccines include Ad, FPV, attenuated YFV, and vaccinia virus vectors, all of which are relevant as potential human viral vectored vaccines as witnessed by
the number of clinical trials now completed or underway (Draper and Heeney 2010).
Table 4.3 reports a summary of viral-vectored vaccines and prime-boost combinations
that have advanced to clinical trials highlighting the preponderance of poxvirus and
Ad vectors. The initial clinical experience with adenovirus as vaccine was based on
the use of Ad5 derived vectors as candidate vaccines for HIV-1 and other pathogens
including malaria parasite and influenza virus. Despite the potent immunogenicity,
this approach suffered a setback when an Ad5 HIV-1 vaccine (“STEP trial”) failed
to reduce, and might even have increased, the rate of HIV infection in men who
were uncircumcised and who had preexisting antibodies specific for Ad5 (Buchbinder
et al. 2008; McElrath et al. 2008). However, recent analyses of this trial did not
confirm the causal correlation between Ad5 serostatus and increased acquisition of
HIV (Hutnick et al. 2009; O’Brien et al. 2009) and there is continued interest in
pursuing Ad vectors, either in combination approaches with other vaccine vectors or
using human serotypes with low seroprevalence, or those derived from chimpanzees.
Recently, Barnes and colleagues showed that is possible to generate T cell responses
against HCV of a magnitude and quality associated with protective immunity in
healthy adults using a simian adenoviral vector vaccine (Barnes et al. 2012). A
different simian adenovirus vaccine encoding a malaria antigen also induced a very
potent and long lasting T cell response (Colloca et al. 2012; O’Hara et al. 2012;
Sheehy et al. 2011) in humans.

MVA-based vaccines against HIV/Acquired Immune Deficiency Syndrome
(Vasan et al. 2010) malaria (Moorthy et al. 2004a, b), TB (Hawkridge et al. 2008),
Human papilloma virus-induced cervical intraepithelial neoplasia (Corona et al.
2004) and melanoma (Smith et al. 2005a, b) are being evaluated in human clinical
trials and a Phase I study of an alphavirus-based vaccine against cytomegalovirus
has been completed (Bernstein et al. 2009).

The prime-boost strategy with heterologous vectors is showing promise in clinical
trials, as indicated by the moderately successful RV 144 trial (Rerks-Ngarm et al.
2009). This study, conducted in Thailand with more than 16,000 study participants,
showed a statistically significant trend towards preventing HIV infection in an at-risk
population. The vaccine regimen employed a heterologous prime-boost strategy
comprising a canarypox vector (ALVAC-HIV, Sanofi Pasteur) followed by a gp120
protein subunit in ALUM adjuvant (AIDSVAX B/E, Global Solutions for Infectious
Diseases). As a booster vaccination, the AIDSVAX B/E vaccine achieved protective
immunity, despite the previous lack of efficacy of AIDSVAX B/E alone in a Phase
III trial. This highlights a key property of viral vectors as vaccine platforms in that
they can be combined in a plethora of permutations to achieve the desired immuno-
logical endpoint.

Another example of a prime-boost protocol in the clinic is the PAVE 100 study,
redesigned as HVTN 505. This DNA-adenovirus prime-boost vaccine includes
three HIV-1 envelopes (clades A, B, and C), as well as gag, pol and nef (IAVI report
2011). The results from a Phase IIA randomized clinical trial of a multiclade HIV-1
DNA prime followed by a multiclade Ad5 HIV-1 vaccine boost in healthy adults
(HVTN204) has been recently published (Churchyard et al. 2011) showing that
the vaccine regimen was well-tolerated and induced polyfunctional CD4+ and CD8+
T cells. Still other prime-boost strategy uses DNA and MVA vectors expressing many different HIV antigens (Rerks-Ngarm et al. 2009).

Based on preclinical studies showing that adenovirus prime followed by MVA boost is a powerful strategy to induce potent and durable T-cell responses this protocol has now entered clinical testing with excellent results. Several recent studies have shown the induction of broad, potent and sustained CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in human volunteers after priming with simian adenoviral vectors and boosting with MVA encoding for antigens derived from Plasmodium falciparum (Hill et al. 2010; O’Hara et al. 2012; Sheehy et al. 2011).

### 4.5 Conclusions and Perspectives

Viral vectors can be manufactured at large scale, thermostable formulations are available (Alcock et al. 2010) and sufficient clinical research has now been conducted to establish that replication deficient viral vectored vaccines lead the genetic vaccine field in inducing strong and broad responses. Moreover, efficacy studies of T cell inducing vaccines against a number of diseases in preclinical models are finally demonstrating that this is a valid approach to filling the gaps in our defense against not only infectious disease, but some forms of cancer.

There is an array of choices for vectored vaccine development, and it is apparent that success of a specific vaccine application will reflect in large part vector selection. The first consideration in choosing a vector is whether it will be used in a prophylactic or therapeutic application. In people already infected with an infectious agent such as HIV, the benefit of a therapeutic vaccine in an attempt to awake or strengthen immune response to finally clear infection may outweigh some risk attributed to the vector itself. In contrast, prophylactic vaccines are intended for healthy people, not only adults, but also children and infants. Therefore, safety is of paramount importance. With regard to HIV vaccines, there is a real possibility of potential vaccinees in target populations being already HIV-positive and perhaps immune suppressed, making safety of viral vectors of great importance.

Vector selection also requires a thorough understanding of the biology of the infectious agent for which the vaccine is being developed and knowledge of the course of the resultant disease. Natural recovery from disease will often highlight immune responses correlated with control or eradication of the infectious agent, providing critical information with regard to the type of immune response desired: cellular and/or humoral, systemic or mucosal. Indeed, the various vaccine vectors have the ability to differentially induce immune response components, as shown in Table 4.2. The mode of transmission of the infectious agent will also impact vector choice and vaccination route (i.e. systemic or mucosal).

Practical considerations are as important as the scientific ones. The final goal once the vaccine has proven to be effective in clinical trials is to develop a manufacturing strategy able to provide vaccine doses for use in millions of people worldwide. A system for large scale production must be available, and the viral recombinant must be genetically stable in order to maintain its integrity through multiple
passages in order to reach desired quantities of vaccine material. Additionally, global indication of a vaccine implies use in the developing world where intact cold chain for shipping, distribution and storage and sophisticated equipment for vaccine administration are not always available. Therefore, vaccines that are physically stable, and that do not require freezing or even refrigeration are preferable, as are “needleless” vaccines, such as those that can be administered by intranasal or oral routes. These alternative administration routes can enhance convenience, safety, elicit both local and systemic immune responses; thus potentially provide protection from pathogens at the site of entry. Recombinant Ad5 encoding HIV-1 antigens has been successfully lyophilized and embedded in enteric-coated capsules that resist to acidic stomach environment and deliver vaccine directly to the intestinal tract. Oral immunization of macaques with these capsules primed antigen-specific mucosal and systemic immune responses (Mercier et al. 2007). The nasal route offers one of the most promising opportunities for vaccine administration and innovative strategies used by researchers and industry include new mucosal adjuvants, mucoadhesive polymers for prolonged exposure to mucosal vaccines and intranasal delivery systems such as the spray device of FluMist (AstraZeneca Canada Inc), the first intranasal influenza vaccine on the market. Adenovirus-based vaccines might be among the best candidate for nasal delivery given their natural tropism for the nasal mucous membrane and their ability to activate innate immune responses (Tutykhina et al. 2011). Even the skin, known to be a highly immunogenic vaccination site, due to ease of access to immune system and microvasculature but considered unpractical as conventional intradermal injection is a complex and unreliable procedure requiring skilled personnel, is gaining new interest thanks to recently developed minimally invasive technologies including vaccine-coated, solid or dissolving microneedle patches, currently under preclinical evaluation for protein, DNA and viral vector vaccines (Carey et al. 2011).

The field of viral vector vaccines is highly dynamic and the development of products based on viral vectors will be accompanied in the next years by advances in technology for vector manufacturing and stability, vaccine administration and enhancement of vaccine-induced immunity overcoming the immunodominance of vector antigens over transgenic antigens. Despite the complexities posed by protocol optimization and heterologous prime-boost vaccine regimens, the strategy holds enormous promise for the prevention of a range of infectious diseases and immunotherapy of cancer.

References

Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, Hanlon M, Spencer AJ, Honeycutt JD, Wyllie DH, Gilbert SC, Bregu M, Hill AV (2010) Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2:19ra12

Antoine G, Scheifflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia strain: comparison with other orthopoxviruses. Virology 244:365–396
Appaiahgari MB, Vrati S (2010) IMOJEV(R): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vacc 9:1371–1384

Appledorn DM, Aldhamen YA, Depas W, Seregin SS, Liu CJ, Schultt N, Quach D, Quiroga D, Godbehere S, Zlatkin I, Kim S, McCormick JJ, Amalfitano A (2010) A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One 5:e9579

Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyn ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R (2011) Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis 204:1541–1549

Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849–862

Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, Liao HX, Kepler TB, Haynes BF, Ramsburg E (2008) Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26:6108–6118

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus A, Ammendola V, Naddeo V, O’Hara V, Willberg C, Harrison A, Graziofi P, Esposito ML, Siiani L, Traboni C, Oo Y, Adams D, Hill AS, Colloca S, Nicosia A, Cortese R, Klenerman P (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111

Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5:386–390

Beignon AS, Mollier K, Liard C, Coutant F, Munier S, Riviere J, Souque P, Charneau P (2009) Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 83:10963–10974

Bernstein DI, Reap EA, Kate N, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD (2009) Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484–493

Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR (2010) Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 28:7881–7889

Bokhoven M, Stephen SL, Knight S, Gevers EF, Robinson IC, Takeuchi Y, Collins MK (2009) Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol 83:283–294

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893

Buffa V, Negri DR, Leone P, Bona R, Borghi M, Bacigalupo I, Carlei D, Sgadari C, Ensoli B, Cara A (2006) A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J Gen Virol 87:1625–1634

Capone S, Reyes-Sandoval A, Naddeo M, Siiani L, Ammendola V, Rollier CS, Nicosia A, Colloca S, Cortese R, Folgori A, Hill AV (2010) Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29:256–265

Carey JB, Pearson FE, Vrdoljak A, McGrath MG, Crean AM, Walsh PT, Doody T, O’Mahony C, Hill AV, Moore AC (2011) Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS One 6:e22442
Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigon W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver J (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305–6313

Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, McKelvey T, Chastain M, Gurunathan S, Tartaglia J, Emini EA, Shiver J (2004) Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78:11434–11438

Catanzaro AT, Koup RA, Roederer M, Bailer RT, Moodie Z, Groves D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194:1638–1649

Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M, Wu TC (2002) Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13:553–568

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6:e21225

Collins MK, Cerundolo V (2004) Gene therapy meets vaccine development. Trends Biotechnol 22:623–626

Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani A, Naddeo M, Grazioli F, Esposito ML, Ambrosio A, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O’Hara GA, Ewer KJ, Anagnostou Bliss, Hill AV, Traboni C, Kleenerman P, Cortese R, Nicosia A (2012) Vaccine vectors derived from a large collection of Simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4(115):ra112

Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes R, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R (2004) Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15:421–431

Coutant F, Frenkiel MP, Despres P, Charneau P (2008) Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3:e3973

Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Omlsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE (2002) Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53:209–211

Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8:62–73

Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV (2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14:819–821

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV (2010) Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185:7583–7595

Duerr A, Wasserheit JN, Corey L (2006) HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43:500–511
Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC (2007) A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 13:3999–4008

Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, MacDonald HR (2003) In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111:1673–1681

Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, Ertl HC, Wilson JM (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75:11603–11613

Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, Giles-Davis W, Wilson JM, Ertl HC (2003) A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170:1416–1422

Foged C, Hansen J, Agger EM (2011) License to kill: formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci. doi:10.1016/j.ejps.2011.08.016

Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J (2004) Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vacc 3(4 Suppl):S75–S88

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellanga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ (2011) Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 85:4222–4233

Greer CE, Zhou F, Legg HS, Tang Z, Perri S, Sloan BA, Megedez JZ, Uematsu Y, Vajdy M, Polo JM (2007) A chimeric alphavirus RNA replicon gene-based vaccine for human paramyxovirus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25:481–489

Gupta S, Zhou F, Greer CE, Legg H, Tang T, Luciw P, zurMegeze J, Barnett SW, Donnelly JJ, O’Hagan DT, Polo JM, Vajdy M (2006) Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses 22:993–997

Harro C, Sun X, Stek JE, Leavitt RY, Mehrrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E (2009) Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vac Immunol 16:1285–1292

Hawkridge T, Scribe TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldman A, Hatherill M, Merwe L, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198:544–552

He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr (2005) Immunization with lentiviral vector- transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174:3808–3817

Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vac 6:78–83

Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD (1996) Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741–3752

Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP (2008) MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol 180:3339–3346

Holst PJ, Bassi MR, Thomsen AR, Christensen JP (2010) DNA fusion gene vaccines. Curr Opin Mol Ther 12:47–54
Holst PJ, Christensen JP, Thomsen AR (2011) Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice. J Immunol 18:3997–4007

Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC (2004) Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22:3993–4001

Hu B, Yang H, Dai B, Tai A, Wang P (2009) Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 20:1652–1664

Hu B, Dai B, Wang P (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28:6675–6683

Hu B, Tai A, Wang P (2011) Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 239:45–61

Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR (2009) Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 15:876–878

IAVI Report: IAVI database of AIDS vaccines in human trials. http://www.iavireport.org/trialsdb. Accessed 30 Dec 2011

Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, Charneau P (2007) Lentiviral vectors encoding HIV-1 polypeptides induce broad CTL responses in vivo. Mol Ther 15:1203–1210

Kahl CA, Bonnell J, Hiriyananna S, Fultz M, Nyberg-Hoffman C, Chen P, King CR, Gall JG (2010) Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28:5691–5702

Karwacz K, Mukherjee S, Apolonio L, Blundell MP, Bouma G, Escors D, Collins MK, Thrasher AJ (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83:3094–3103

Kim PS, Ahmed R (2010) Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22:223–230

Lasaro MO, Ertl HC (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17:1333–1339

Lasaro MO, Tatsis N, Hensley SE, Whittle JC, Lin SW, Rux J, Wherry EJ, Cohen GH, Eisenberg RJ, Ertl HC (2008) Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 14:205–212

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamschikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koupa R, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS (2010) A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29:304–313

Lemkert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79:9694–9701

Liu MA (2010) Gene-based vaccines: recent developments. Curr Opin Mol Ther 12:86–93

Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87–91

Lopes L, Dewannieux M, Takeuchi Y, Collins MK (2011) A lentiviral vector pseudotype suitable for vaccine development. J Gene Med 13:181–187

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894–1905

Mercier GT, Nehete PN, Passeri MF, Nehete BN, Weaver EA, Templeton NS, Schluns K, Buchl SS, Sastry KJ, Barry MA (2007) Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25:8687–8701
Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72:1031–1038
Montini E, Cesana D, Schmidt M, Sanvito F, Ponzioni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C, Naldini L (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687–696
Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV (2004a) Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 189:2213–2219
Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS (2004b) A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1:e33
Nardin E (2010) The past decade in malaria synthetic peptide vaccine clinical trials. Hum Vaccin 6:27–38
Naslund TI, Kostic L, Nordstrom EK, Chen M, Liljestrom P (2011) Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J 8:36
Negri DR, Michelinì Z, Baroncelli S, Spada M, Vendetti S, Buffa V, Bona R, Leone P, Klotman ME, Cara A (2007) Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15:1716–1723
Negri DR, Michelinì Z, Bona R, Blasi M, Filati P, Leone P, Rossi A, Franco M, Cara A (2011) Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther 11:739–750
O’Brien KL, Liu J, King SL, Nordstrom EK, Chen M, Liljestrom P (2011) Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J 8:36
Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, Romero RE, Tang Z, Bin Q, Dubensky TW Jr, Vajdy M, Otten GR, Polo JM (2003) An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene vaccine delivery vector. J Virol 77:10394–10403
Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, Mallet J, Serguera C (2006) Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 103:17684–17689
Priddd FH, Brown D, Kublin J, Monahan K, Wright DP, Lalazari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNobile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/neo vaccine in healthy adults. Clin Infect Dis 46:1769–1781
Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J (2010) The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 17(11):1687–1694

Rerks-Ngarm S, Pititsuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, PremSri N, Namwatt C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stabilein D, Birx DL, Chunsuittiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220

Reyes-Sandoval A, Ertl HC (2001) DNA vaccines. Curr Mol Med 1:217–243

Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC (2004) Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 78:7392–7399

Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38:732–741

Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosa A, Colloca S, Cortese R, Hill AV (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78:145–153

Roberts DM, Nanda A, Havenga MJ, Aibbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Liffton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH (2006) Hexon-chimeraic adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239–243

Roy S, Medina-Jaszek A, Wilson MJ, Sandhu A, Calcedo R, Lin J, Wilson JM (2011) Creation of a panel of vectors based on ape adenovirus isolates. J Gene Med 13:17–25

Schirmbeck R, Reimann J, Kochanek S, Kreppel F (2008) The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 16:1609–1616

Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks M, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosa A, Hill AV, Draper SJ (2011) Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19:2269–2276

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang QZ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Kersock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Liffton MA, Kuroda MJ, Schmitz JE, Letvinn NL, Caulfield MJ, Bett AJ, Youl R, Kaslow DC, Emini EA (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335

Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V (2005a) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113:259–266

Smith CL, Mirza F, Pasqueto V, Tscharke DC, Palmowski MJ, Dunbar PR, Sette A, Harris AL, Cerundolo V (2005b) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175:8431–8437

Soloff AC, Liu X, Gao W, Day RD, Gambotto A, Barratt-Boyes SM (2009) Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection. Eur J Immunol 39:2437–2449
Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus AD (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700–3709

Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmitt J, Jahrling PB, Nabel GJ (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3:e177

Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616–629

Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, Gao GP, Wilson JM, Ertl HC (2006) Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13:421–429

Thornburg NJ, Ray CA, Collier ML, Liao HX, Pickup DJ, Johnston RE (2007) Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology 362:441–452

Tutykhina IL, Logunov DY, Shcherbinin DN, Shmarov MM, Tukhvatulin AI, Naroditsky BS, Gintsburg AL (2011) Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med 89:331–341

Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa HY, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Daily L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD (2010) Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 5:e8816

Wang HB, Kondo A, Yoshida A, Yoshizaki S, Abe S, Bao LL, Mizuki N, Ichino M, Klinman D, Okuda K, Shimada M (2010) Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther 17:4–13

Wanisch K, Yanez-Munoz RJ (2009) Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 17:1316–1332

Wyatt LS, Earl PL, Eller LA, Moss B (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101:4590–4595

Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC (2002) Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76:2667–2675

Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, Kuller L, Polo JM, Barnett SW, Stamatatos L (2006) Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22:1022–1030

Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, Wang P (2008) Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 26:326–334